Drug Discovery Targeting Drug-Resistant Bacteria

Häftad, Engelska, 2020

2 022 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.

Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.

Written by scientists with extensive industrial experience in drug discovery
Provides a balanced view of the field, including its challenges and future directions
Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

Produktinformation

Utgivningsdatum:2020-05-15
Mått:191 x 235 x undefined mm
Vikt:880 g
Format:Häftad
Språk:Engelska
Antal sidor:432
Förlag:Elsevier Science
ISBN:9780128184806

Utforska kategorier

Farmakologi inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin
Organisk kemi inom Naturvetenskap och teknik

Mer om författaren

Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya University, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience across various countries. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has published many articles in well-reputed journals and a large number of books. He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award, and “SERB-Ramanujan Fellowship Award. He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community. Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens. Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.

Recensioner i media

"This book provides quality information and is a good educational tool." --Doody

Innehållsförteckning

1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria